Condition: ALK Positive Non-small Cell Lung Cancer · Sponsor: Guangdong Association of Clinical Trials
This phase II study is aim to investigate the efficacy, resistance mechanism, safety profile of first-line lorlatinib in China advanced ALK+ non-small cell lung cancer (NSCLC). Participants will receive continuous daily PO dosing of lorlatinib 100mg QD.
This description comes directly from the study's public registry record.
Jiaxin Lin, PhD · +8618928737479 · linjiaxin@gdph.org.cn
Always discuss trial participation with your own doctor first.
| Guangdong Provincial Perople's Hospital | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06092086